source
- Why pediatric rare oncology outperforms in a volatile biotech marketReal progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investm…BioSpace · 13m ago↗ source
- Merck and Moderna report success in late-stage trial of personalized mRNA cancer vaccineMerck and Moderna announced that their personalized mRNA cancer vaccine achieved its primary endpoint in a randomized late-stage trial, marking the first demonstration that such an approach can be…